Aura Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.13 M
as on 15-06-2024
- Paid Up Capital ₹ 5.13 M
as on 15-06-2024
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.62 Cr
as on 15-06-2024
- Revenue 17.79%
(FY 2023)
- Profit 35.47%
(FY 2023)
- Ebitda 38.94%
(FY 2023)
- Net Worth 32.13%
(FY 2023)
- Total Assets 23.90%
(FY 2023)
About Aura Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.13 M and a paid-up capital of Rs 5.13 M.
The company currently has active open charges totaling ₹16.62 Cr.
Sultanali Mulani, Santosh Dsouza, and Suraj Viswanadhan serve as directors at the Company.
- CIN/LLPIN
U24239MH2009PTC197919
- Company No.
197919
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aura Pharmaceuticals Private Limited offer?
Aura Pharmaceuticals Private Limited offers a wide range of products and services, including Packaging Foil, Aluminum Foils, Packaging Caps & Seals, Metal Caps, Labels, Bottle Labels.
Who are the key members and board of directors at Aura Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sultanali Mulani  | Director | 02-Mar-2012 | Current |
| Santosh Dsouza | Director | 17-Dec-2009 | Current |
| Suraj Viswanadhan | Director | 17-Dec-2009 | Current |
Financial Performance of Aura Pharmaceuticals.
Aura Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 17.79% increase. The company also saw a substantial improvement in profitability, with a 35.47% increase in profit. The company's net worth Soared by an impressive increase of 32.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aura Pharmaceuticals?
In 2023, Aura Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aura Lifecare Private LimitedActive 12 years 6 monthsSultanali Mulani and Santosh Dsouza are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Aug 2021 | ₹5.50 Cr | Open |
Yes Bank Limited Creation Date: 25 Sep 2013 | ₹11.12 Cr | Open |
How Many Employees Work at Aura Pharmaceuticals?
Aura Pharmaceuticals has a workforce of 76 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aura Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aura Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
